Merck Serono Says Partnering Part Of Its Future, Seeks Anti-PD-L1 Deal
This article was originally published in The Pink Sheet Daily
Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.
You may also be interested in...
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.
A discussion with internal and external experts restarts clinical development of atacicept for lupus after a two-year hiatus.
Merck Serono will conduct a second Phase III study of lung cancer vaccine tecemotide in patients treated concurrently with chemotherapy and radiation. The START trial, which also dosed patients receiving sequential therapy, failed but the predefined, concurrently treated subgroup showed greater median overall survival compared to placebo.